What is OLGRAM?
Founded in 2019 and headquartered in BREHAN, France, OLGRAM is dedicated to harnessing the power of marine molecules to address the critical challenge of bacterial infections. The company's innovative approach targets the prevention and control of these infections, offering a promising new avenue in the pharmaceutical and biotechnology landscape. OLGRAM's focus on natural, marine-derived compounds distinguishes it within the competitive biotech sector, aiming to provide effective and potentially less resistant alternatives to traditional antibiotics.
How much funding has OLGRAM raised?
OLGRAM has raised a total of $1.8M across 1 funding round:
Angel/Seed
$1.8M
Angel/Seed (2021): $1.8M with participation from Bpifrance
Key Investors in OLGRAM
Bpifrance
Bpifrance is a French public investment bank that finances companies at all stages of development, supporting their credit, guarantees, equity, innovation projects, and international expansion. They also provide consulting and networking services for entrepreneurs.
What's next for OLGRAM?
With the recent major strategic investment, OLGRAM is poised to advance its pipeline of marine-derived therapeutics. This substantial backing is expected to fuel critical research initiatives, scale up production capabilities, and potentially expand clinical trials. The company's trajectory suggests a move towards broader market penetration and the establishment of its unique solutions as a significant player in the global fight against bacterial infections. Future developments will likely focus on translating laboratory discoveries into viable commercial products.
See full OLGRAM company page
